Market Intelligence
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
CGT Is In Its Infancy For CNS Disorders, But Technical Strides Being Made
Technical challenges and lackluster investor sentiment about the near-term commercial potential of cell and gene therapies in neurological disorders may be holding the field back.
Deals in Depth: February 2024
Just one $1bn+ alliance was penned in February, compared to ten in the previous month. In the top alliance by deal value, Neomorph and Novo Nordisk entered into a potential $1.46bn agreement for the discovery, development, and commercialization of molecular glue degraders (MGDs) for cardiometabolic and rare diseases. The collaboration brings together Novo Nordisk's expertise in those disease areas with Neomorph's MGD discovery platform. Neomorph will lead discovery and preclinical activities against selected targets with Novo Nordisk having the right to exclusively pursue further clinical development and commercialization of the compounds.
Nouscom Aims To Ride Neoantigen Cancer Vaccine Wave
Nouscom, with one major partner and strong confidence, is building research and manufacturing foundations to address significant market needs with its neoantigen cancer vaccine platform.
AI Uses During Lifecycle Of Medicinal Products And Medical Devices: An EU Regulatory Perspective
Despite expectations in some circles in December 2023 that adoption of the EU AI Act was imminent, the scope of the final text and when it will be published remain unclear. There are, however, related consequences that can be anticipated.
What Big Pharmas Are Looking For In Partners
With all signs pointing towards a year ripe with partnering opportunities, four big pharma dealmakers reveal what they are looking for.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
Fewer Acquisitions And Alliances In 2023, But Valuations Increased
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Almirall Goes All In On Generative AI
Dermatology-focused Almirall S.A. is partnering with Microsoft for generative artificial intelligence capabilities. It is the second generative AI-based collaboration announced by Almirall in several months.
Deals in Depth: January 2024
Ten $1bn+ alliances were penned in January. In the top alliance by deal value, Shanghai Argo Biopharmaceutical entered into exclusive collaboration with Novartis Pharma for two undisclosed Argo cardiovascular disease programs, one in Phase I and another in Phase I/IIa. Novartis gets an exclusive global license to develop and commercialize the Phase I program and also receives an option to potentially license compounds directed against up to two additional targets. For the Phase I/IIa program, Novartis gets an exclusive license worldwide except in Greater China. The deal could be worth up to $4.17bn for Argo.
Dealmaking Quarterly Statistics, Q4 2023
During Q4, biopharma merger and acquisition deal value reached $63bn and drew in $75.4bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $3.4bn.
Unraveling #JPM24: Insights From Citeline Reporters And Analysts
As it often does, this year's J.P. Morgan Healthcare Conference could set the tone for the rest of the year in biopharma. In Vivo revisits the key questions coming out of the 2024 event.
The Next Mega-Blockbusters Are Already Approved
The success of a drug depends on investment and lifecycle management. Keytruda is the most valuable drug in the industry, while trendy GLP-1 agonists are a prominent drug class.
Financing Quarterly Statistics, Q4 2023
During the fourth quarter, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $1.1bn; while in vitro diagnostic firms and research tools players raised $459m.
Ups And Downs Of Anti-TIGIT Development
Once heralded with optimism, the class of anti-TIGIT molecules has since fallen out of favor, plagued by a succession of disappointing findings.
The Top Five Pharma Stories Of 2023
The biopharma new year begins as the J.P. Morgan Healthcare Conference ends so here in no particular order, we take a look at five of the biggest stories of 2023, once again a year of highs and lows for the industry.
Deals in Depth: December 2023
Six $1bn+ alliances were penned in December. In the top alliance by deal value, Biokin and its SystImmune subsidiary licensed Bristol Myers Squibb exclusive rights to develop and commercialize its cancer candidate BL-B01D1 worldwide, excluding Mainland China where SystImmune retains rights. BMS will pay $800m up front, up to $500m in contingent near-term payments, and up to $7.1bn in development, regulatory, and sales milestones, for a total potential consideration of up to $8.4bn.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.